BioNTech SE has announced a strategic global partnership with Bristol Myers Squibb to jointly develop and commercialize their bispecific antibody candidate, BNT327, aimed at a variety of solid tumor types. The collaboration leverages the expertise and resources of both companies, with a focus on accelerating the clinical development, potential regulatory approvals, and market launches of BNT327. This partnership will involve a 50:50 profit and loss sharing agreement and aims to establish BNT327 as a new treatment standard beyond traditional checkpoint inhibitors. BioNTech and Bristol Myers Squibb will work together to conduct an extensive clinical development program for BNT327, both as a monotherapy and in combination with other treatments, with the potential to expand indications and combinations independently.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.